Geographical area | No. of positive cases/No. of examined cases (%) | Genotype (n) | Reference |
---|---|---|---|
Peru | 105/2672(3.9) | Peru-1 (35), Peru-2 (18), Peru-3 (1), Peru-4 (1), Peru-5 (3), Peru-6 (1), Peru-7 (8), Peru-8 (4), Peru-9 (9), Peru-10 (3), Peru-11 (6) | [11] |
Nigeria (Benin City) | 77/463(16.6) | D (31); A (22); TypeIV (14); CAF 2 (2); Eebp A(1); Peru 8 (1); DÂ +Â IV (1); Nig1 to Nig4 (one each) | [32] |
Nigeria (Lagos) | 5/90(5.6) | TypeIV (4); one mixed with two unknown genotypes | [10] |
Nigeria (Ibadan) | 10/132(7.6) | Peru 8 (1); Nig2 (2); new genotype (1); D (1); TypeIV (5); | [48] |
Thailand | 5/90(5.6%) | D(5) | [33] |
Iran | 6/15(40) | D (3); E (3); | [49] |
Nigeria (Benin City) | 18/285(6.3) | Nig4 (2); TypeIV (1); Nig6 (10); Nig7 (2); three with mixed genotypes | [58] |
Tunisiana | – | D (4);B (2); Peru (1) | [50] |
Congo (Kinshasa) | 19/242(7.8) | NIA1 (2); D (2); KIN1 (5); KIN2 (5); KIN3 (5); | [51] |
Iran | 8/356(2.2) | D (−); K (−); | [18] |
Cameroon | 8/154(5.2) | TypeIV (8); | [59] |
Australia (Sydney) | 29/159(18.2) | B (29); | [60] |
Niamey | 24/228(10.5) | A (10); K (1); CAF1 (2); NIA1 (3); D (1); | [53] |
Hanoi | 3/42(7.1) | D (1); E (1); HAN1 (1) | [53] |
Thailanda | – | D (12);E (5); PigEBITS7 (4); S (4); Peru (2); O (1); R (1); T (1); U (1); V (1); W (1); | [54] |
China (Henan) | 39/683 (5.7) | EbpC (18); D (7); TypeIV (6); PigEBITS7 (1); EbpD (1); Peru8 (1); Henan-I to Henan-V (one each) | [29] |
Malawi and Netherlandsa | – | A(1), B(4), C(5), D(6), K(14), S1(2), S2(11), S3(2), S4(1), S5(4), S6(2); S7(1), S8(1), S9(1), 2 unnamed subtypes | [61] |
India | – | Lnd1–4 | [62] |
China (Guangxi) | 33/285(11.6) | D (11); TypeIV (8); PigEBITS7 (7); EbpC (1); GX25 (1); GX456 (1); GX458 (1) | The present study |